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Abstract Potential antioxidant properties of therapeutically 
achievable concentrations of the protonated, active form of 
omeprazole (OM) were investigated in vitro at specific acidic pH 
values to mhnic intragastric onditions in the clinical setting. We 
found that OM is a powerful scavenger of hypochlorous acid 
(HOCI) ewn at a drug concentration of 10 pM at pH of 5.3 or 
3.5. This effect is also evident in the presc, nce of the physiological 
HOC! scavenger ascorbate. M~reover, 10 and 50 IxM OM 
Inhibit significantly both iron-and copper-eriven oxidant damage 
at pH $.3 and 3.$, respeetivel~. Since oxidative stress is Involved 
the gnstrle Injury of peptic ulcer and gastritis, it may be 
hypothesized that some therapeutical effects of OM could also be 
related to its untioxidant properties. 
Key words: Omeprazole; Hypochlorous acid; Iron; Copper; 
Oxidative stress; Antioxidant 
1. Introduction 
2. Materials and methods 
Reagents were from Sigma Aldrich s.r.l., Milano, Italy, except for 
OM, which was a generous gift of Astra, Sodertalje, Sweden. Proce- 
dures were carried out in plastic or acid-washed glassware, and solu- 
tions were prepared in Chelex 100 resin-treated glass-bidistilled water. 
The protonated form of OM was obtained by adding the native drug 
to 5 mM HCI, and used at final concentrations of 10, 50 and 100 ~tM. 
Biochemical tests were specifically carried out at acidic pH values, 
which may correspond to those of acute gastric inflammatory areas 
and of the intragastric pH reached after drug treatment in circ. I~ 
this regard, it has been shown that inflammatory phagocytic cells 
,qe,:rete H + and can acidify the pericellular environment a pH levels 
of about 3.5 [13]; back-diffusion of acid through damaged gastric 
mucosa [14] could also favour these relatively low pH values in ulcer 
tissues. Furthermore, it has been reported that the mean intragastric 
pH is approx. 5.3 after OM therapy in humans [15]. Antioxidant 
effects of protonated OM were not investigated atpH 7.4, since the 
active drug is not formed at physiological pH velues of the blood- 
stream [I]. Possible antioxidant activity of the unprotonated form of 
OM (which is poorly water-soluble) was also not investigated, con- 
sidering that it does not represent the active drug in the clinical set- 
ting. 
Omeprazole (OM) is an inhibitor of the proton pump of the 
gastric parietal cells widely used for the treatment of peptic 
ulcer and gastritis. OM is a lipophilic weak base [1]~. so that it 
is in its unprotonated and inactive form at physiological pH 
of the bloodstream, but accumulates in acidic environments 
[1], such as in parietal cells and, conceivably, in gastric inflam- 
matory domains, which are characterized by low pH values 
and increased vascular permeability. OM, therefore, is a pro- 
drug, which in an acidic pH becomes cor -,rted to its active 
form, a sulfenamide, by protonation [1]. This sulfenamide, 
besides an anti-secretory activity, could also have some anti- 
oxidant effects. Indeed, similar compounds, namely sulfona- 
mides, chemically react with hypochlorous acid (HOCI) [2], 
which is the most toxic and abundant oxidant generated by 
phagocytes [2-4]. These cells are relevant in inflammatory 
gastric injury, especially in the presence of Helicobacter priori 
[5,6]. Moreover, the benzimidazolic structure of OM [1] sug- 
gests possible inhibitory interactions with catalytic transition 
metals. We have indeed reported similar antioxidant proper- 
ties for the imidazolic drug cimetidine [7]. Notably, redox- 
active transition metals are crucial in oxidant generation 
and oxidative stress [3,4,8], which play a role in the pathogen- 
esis of peptic ulcer and gastritis [5,9-12]. 
The present study was designed to investigate potential 
antioxidant effects of the protonated, active form of OM in 
specific experimental models. The results show that this drug 
is a powerful scavenger of HOCI and, additionally, it can 
counteract iron-and copper-mediated oxidant injury. 
*Corresponding author. Fax: (39) (871) 345501, or 
(39) (871) 355267. 
2.1. HOC! scavenging 
We have used the 13-carotene test to assess cavenging properties of 
OM against HOCI [7,16]. Indeed, it is known that HOC! induces 13- 
carotene oxidation and bleaching [4,7,16,17], which can be counter- 
acted by HOCI scavengers 1"716]. Since ascorbic acid is present in the 
gastric juice [18] and it can scavenge HOCI [4], potential scavenging 
capacity of OM against HOCI was investigated not only with the drug 
alone but also in the presence of ascorbate; moreover, specific anti- 
oxidant effects of ascorbate alone were studied. In this context, mean 
intragastric ascorbic acid concentrations of about 20 and 70 ttM have 
been shown in patients with peptic ulcer or gastritis and in healthy 
subjects, respectively [18]. 
Reaction mixtures contained !.8 gM 13-carotene in 20 mM 
K2HPO4-HCI, pH 5.3 or 3.5, with and without protonated OM or 
20 and 70 ttM ascorbic acid or OM plus ascorbate. HOCI was added 
at 'physiologically' relevant final concentrations of 70 ttM [4,7,16] to 
start the reaction, followed by 10 min incubation at 25°C; the 13- 
carotene-related absorbance values at 451 nm (A451) were then re- 
corded spectrophotometricaily gainst appropriate drug.containing 
blanks to assess pecific antioxidant effects. 
The concentrations of NaOCl-derived HOCi were calculated using 
a molar extinction coefficient of 100 M -I cm -1 at 235 nm [19]. 
2.2. Iron.and copper.driven oxidant injury 
The redox-active transition metals iron and copper can oxidize the 
sugar deoxyribose [4,20,21], which is an integral component of DNA 
[4]. Iron-and/or copper-related oxidizing species generated at target 
molecular sites are relevant in conditioning oxidant injury in vivo 
[4,8,22,23], and they are involved in metal-dependent deoxyribose 
oxidation in the absence of the non-physiological chelator EDTA 
but in the presence of phosphates [4,20,21], which are physiological 
transition metal complexing agents [24]. Thus, molecules able to bind 
and inactivate catalytic transition metals, removing them from deox- 
yrtbose, can counteract specifically metal-mediated sugar oxidation 
[4,20,21]. Reaction mixtures contained, in a final volume of 1.0 mi, 
the following reagents at the final concentrations stated: 10 mM 
KzHPOa-HCI, pH 5.3 or 3.5, 4.0 mM deoxyribose, 6 ~M FeCia or 
CuCIz, 50 laM H20¢ and 20 ~M ascorbic acid, with or without pro- 
tonated OM. After 30 rain incubation at 37°C, 1.0 ml of 2.~% tri- 
chloroacefic acid and 1.0 ml of 0,6% aqueous olution of thiobari~i- 
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Table I 
Kq'ects of protonated OM with and without ascorbic acid on HOCI.induced ~-carotene bleaching at pH 5.3 
A451 
1.8 pM I~carotene alone 
Control 
(!.8 pM I~carotene plus 70 pM HOCI) 
0.139 + 0.007 
0.023 + 0.005 
Control plus OM 
I0 pM 0.073 + 0.007 a,d 
50 pM 0.140 + 0.009 a-d 
100 pM 0.141 + 0.010 s,c,d 
Control plus 20 pM ascorbate 0.037 + 0.006 a
Control plus 20 pM ascorbate and OM 
10 pM 0.089 + 0,008 ~,d'e 
50 gM 0.142 + 0.01 !~-d 
100 pM 0.143 + 0.012 a'~''d 
Means+S.D. of 5 ex~riments. ~P<0.05 vs control; hP<0.05 VS preceding values; ~P--'NS vs 13-carotene alone; dp<0.05 vs control plus 
ascorbate; ~P < 0,05 vs control plus OM (ANOVA plus Student-Newman-Keuls te t). See sections 2 and 3 for further explanations. 
turic acid (TBA) were added, followed by iS rain heating at 95°C. 
After cooling, the pink ehromogen was read at 532 nm on a double 
beam Varian DMS 200 spectrophotometer against an appropriate 
blank. The drug gave no interference in the TBA test. Results were 
expressed as nmol TBA reactants (TBA.R)/ml, using for calculations 
a molar extinction coefficient of 1.54x 10 ~ M -tcm -t. 
2,& Statistics 
Data were calculated as means + S.D. of 5 different experiments for 
each biochemical test and specific pH value. Specific drug effects were 
evaluated via the one-wa~ analysis of variance (ANOVA) followed by 
the Student-Newman-Keuls test [25]. P < 0.05 was regarded as sta- 
tistically significant [25]. 
3. Results 
3. I. Effects of protonated OM and ascorbic acid on 
HOCl.induced O-carotene bleaching 
As shown in Table l. protonated OM antagonized signifi- 
cantly HOCI,induced I~-carotene bleaching at pH 5,3, resulting 
in about 43% inhibition of I~-carotene oxidation at 10 laM drug 
concentration, and in total inhibition at 50 and 100 ~tM, Sim- 
ilar results were observed at pH 3,5; indeed, the drug gave 
approx, 39% inhibition of HOCI-induced [3-carotene bleaching 
at 10 IzM, and total inhibition beginning from 50 ttM (data not 
shown), HOCI scavenging effects of protonated OM were also 
striking in the presence of ascorbi¢ acid, We will report the 
results obtained at pH 5,3, but a similar experimental trend 
was observed at pH 3,5, Interestingly, 20 ttM ascorbate af- 
forded only little protection against HOCl-induoed I~-carotene 
~3eaching (Table 1), suggesting that the intragastric ascorbate 
concentrations of patients with peptic ulcer and/or gastritis are 
poorly effective at counteracting HOCl-driven oxidant injury. 
In the presence of 20 ttM ascorbate and 10 ttM OM, however, 
marked inhibition of I~-carotene oxidation was observed, 
which was greater than that mediated by each compound 
alone; moreover, OM, even at 10 ttM, was by far more effec- 
tive than ascorbate in HOC! antagonism (Table 1). Hence, the 
HOC! scavenging effects of ascorbate and protonated OM are 
apparently additive, although those of the drug are superior. 
OM, at 50 and 100 ttM, was also totally inhibitory with 20 ttM 
ascorbate (Table !). Under our conditions, 70 ttM ascorbic 
acid gave a near total (i.e. about 92%) antioxidant protection, 
which became effectively total in the presence of each OM 
concentration (not shown). These results are indicative of the 
HOCI scavenging capacity of protonated OM even in the pres- 
ence of the physiological HOCI scavenger ascorbic acid. 
3.2. Effects of protonated OM on iron-and copper.driven 
oxidant injury 
When oxidative reactions were performed at pH 5.3, pro- 
tonated OM showed significant antioxidant effects beginning 
from 10 ~M drug concentration, which resulted in about 20 
and 14% inhibition of iron-and copper-dependent deoxyribose 
o×idation, respectively (Table 2). At pH 3.5, however, proto- 
v.ated OM resulted in a significant antagonism of either iron- 
Table 2 
Effects of protonated OM on iron-and copper-dependent d~xyri- 
bose oxidation at pH 5,3 
Table 3 
Effects of prctonated OM on iron-and copper-dependent deoxyri. 
bose oxidation at pH 3.5 
Iron Copper Iron Copper 
Control 8,55 ± 0,65 3.15 + 0.25 Control 3.3 __. 0.3 2.65 + 0.2 
Control plus OM 
10 pM 6,85 + 0,55 ~ 2,7 ± 0,32 ~ 
50 I~M 5, ! 5 + 0,42 ~,h 2,2 ± 0, I 7 ~'1' 
100 pM 4,5 +-0,28 ~ 1,9 ±0,15 ~
Results are means + S,D, of 5 experiments, and are expressed as 
nmol TBA-PJml, 
°P<0,05 vs control:, bP<0,05 vs the values that precede (ANOVA 
plus Student-Newman-Keuls te t), See section 2 for methodological 
explanations, 
Control plus OM: 
10 ~tM 2.97 + 0.27 2.47 _+ 0.22 
50 pM 2.7 + 0.23" 2. ! + 0.16 a,b 
100 I~M 2.03 + 0.25 a,b 1.85 4- 0.14 a,b 
Results are mcans+S.D, of 5 experiments, and are expressed as 
nmol TBA-R/ml. 
aP<0.05 vs control; bp<0.05 VS the values that precede (ANOVA 
plus Student-Newman-Keuls te t). See section 2 for methodological 
explanations. 
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or copper-mediated deoxyribose oxidation at 50 and 100 ~tM 
drug concentrations (Table 3). Notably, in our model system, 
iron was markedly more prooxidant at pH 5.3 than at pH 3.5; 
a similar phenomenon, although much less evident, was ob- 
served for copper. Thus, the inhibitory effects of protonated 
OM against iron-and copper-med,:.ated oxidant damage are 
more pronounced at pH values of 5.3, which correspond to 
the intragastric ones observed after OM therapy in humans 
[15]. On the other hand, it has been reported that the effects of 
chelating compounds on catalytic transition metal-driven oxi- 
dative damage may be pH-dependent [3,8]. 
4. Discussion 
The present study shows that the protonated, active form of 
OM has significant antioxidant effects against HOCI-and cat- 
alytic transition metal-mediated oxidative injury. 
Phagocyte-derived HOCI oxidizes biologically relevant mo- 
lecules, such as B-carotene [4,7,16,17], which is decreased in 
the gastric juice of patients with inflammatory gastric diseases 
associated with 17. pylori [26], a bacterium stimulating neu- 
trophil oxidant generation [6]. Decreased gastric [3.carotene 
levels may play a role in gastric oxidant damage and carcino- 
genesis [27]. Our data suggest hat protonated OM might 
preserve gastric [3-carotene in vivo through a direct HOCI 
antagonism, and show significant HOCI scavenging effect~ 
of OM also in the presence of the physiological HOCI sca- 
venger ascorbic acid. Notably, with a concentration of ascor- 
bate representative of the mean intragastric concentration of
patients with peptic ulcer or gastritis, i.e. 20 lxM [18], the drug 
continues exerting marked HOCi scavenging activity, suggest- 
ing its specific antioxidant effects in the clinical setting. 
Scavenging of HOCI by OM could also prevent formation 
of monochloramines; these cytotoxic ompounds are gener- 
ated from the interaction of HOCI and ammonia [2,3,28], 
which is largely produced by H. pylori [28]. 
It is remarkable that protonated OM can also bind-inacti- 
vate both iron and copper, presumably through its benzimi- 
dazole ring. Indeed, some imidazolic drugs, such as cimeti- 
dine, bind iron and c,3pper [7,29,30]. Iron is relevant in 
gastric oxidative injury [9,31,32]. Copper is another powerful 
catalytic metal, which typically mediates ite-specific oxidant 
damage [4,21,22]. Transition metal availability in a free =ad 
catalytically active form should be favoured in inflammatory 
diseases, such as peptic ulcer and gastritis. In fact, esp~:ially 
under acidic conditions, white blood cell prooxidants induce 
metal delocalization from iron-and copper-containing proteins 
[3,4,8,33-36], thus promoting oxidative stress. Consistently, 
neutrophil depletion prevents experimental gastric ulceration 
[37], and metal chelators antagonize oxidative injury to gastric 
cells [9,31,32]. 
Under a pharmacological nd therapeutical profile, it 
should be noted that, even if the concentrations of protonated 
OM in selected sites, such as in parietal cells and in acidic 
gastric inflammatory areas, are unknown, relatively high con- 
centrations, conceivably in the mfllimolar range, rr, ay be ex- 
pected, because of drug a~,cumulation in acidic envi~'onments 
and of inflammation-induced increased vascular permeability. 
On the other hand, drug concentrations of about 10 ~tM have 
been shown even in the plasma environment after intravenous 
adhamstration f 40 mg OM in patients with peptic ulcer [38], 
and plasma OM levels up to 14 IIM have been rep~rted in 
subjects given OM by mouth after 7 days of treatment [1]. 
Since OM has inibitory effects on neutrophil function [39], the 
final antioxidant potential of the drug may be even higher in 
rive, resulting from 'direct' and 'indirect' antioxidant mechan- 
isms. OM antioxidant properties, therefore, could be signifi- 
cant in the clinical setting of peptic ulcer and gastritis, which 
are oxidative stress-related conditions [5,9-12]. Indeed, it is 
noteworthy that antioxidant administration improves treat- 
ment outcomes in patients with peptic ulcer [11]. Finally, 
OM antioxidant properties hould be taken into account 
when investigating the levels of oxidizable antioxidants, uch 
as ~-carotene, in the human gastric mucosa and juice. 
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